Is liver transplantation a risk factor for cardiovascular disease? a meta-analysis of observational studies

Liver Transplantation

Volumn 18, Issue 10, 2012, Pages 1140-1146

  Madhwal, Surabhi ^a   Atreja, Ashish ^b   Albeldawdi, Mazen ^b   Lopez, Rocio ^b   Post, Anthony ^a   Costa, Marco A ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; INCIDENCE; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; INCIDENCE; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; RISK FACTORS; SURVIVAL RATE;

EID: 84867567989     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23508     Document Type: Review

References (39)

1. Gordon Burroughs S, Busuttil RW,. Optimal utilization of extended hepatic grafts. Surg Today 2009; 39: 746-751.
2. Pruthi J, Medkiff KA, Esrason KT, Donovan JA, Yoshida EM, Erb SR, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001; 7: 811-815.
3. Pagadala M, Dasarathy S, Eghtesad B, McCullough AJ,. Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl 2009; 15: 1662-1670.
4. Claes K, Meier-Kriesche HU, Schold JD, Vanrenterghem Y, Halloran PF, Ekberg H,. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrol Dial Transplant 2012; 27: 850-857.
5. Watt KD, Charlton MR,. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol 2010; 53: 199-206.
6. Kobashigawa JA,. Statins in solid organ transplantation: is there an immunosuppressive effect? Am J Transplant 2004; 4: 1013-1018.
7. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C,; for American Heart Association and National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
8. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al.; for National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, and American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239.
9. Wells GA, Shea B, O'Connell D, Petersen J, Welch V, Losos M, Tugwell P,. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical- epidemiology/oxford.htm. Accessed June 2012.
10. Jüni P, Witschi A, Bloch R, Egger M,. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999; 282: 1054-1060.
11. Abbasoglu O, Levy MF, Brkic BB, Testa G, Jeyarajah DR, Goldstein RM, et al. Ten years of liver transplantation: an evolving understanding of late graft loss. Transplantation 1997; 64: 1801-1807.
12. Sudan DL, Venkataramani A, Lynch JC, Fox IJ, Shaw BW, Langnas AN,. Causes of late mortality in survivors of liver transplantation. Transplantation 1999; 67: S475A-S507.
13. Rabkin JM, de La Melena V, Orloff SL, Corless CL, Rosen HR, Olyaei AJ,. Late mortality after orthotopic liver transplantation. Am J Surg 2001; 181: 475-479.
14. Vogt DP, Henderson JM, Carey WD, Barnes D,. The long-term survival and causes of death in patients who survive at least 1 year after liver transplantation. Surgery 2002; 132: 775-780.
15. Guckelberger O, Mutzke F, Glanemann M, Neumann UP, Jonas S, Neuhaus R, et al. Validation of cardiovascular risk scores in a liver transplant population. Liver Transpl 2006; 12: 394-401.
16. Borg MA, van der Wouden EJ, Sluiter WJ, Slooff MJ, Haagsma EB, van den Berg AP,. Vascular events after liver transplantation: a long-term follow-up study. Transpl Int 2008; 21: 74-80.
17. Sheiner PA, Magliocca JF, Bodian CA, Kim-Schluger L, Altaca G, Guarrera JV, et al. Long-term medical complications in patients surviving > or = 5 years after liver transplant. Transplantation 2000; 69: 781-789.
18. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J,. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002; 73: 901-906.
19. Neal DA, Tom BD, Luan J, Wareham NJ, Gimson AE, Delriviere LD, et al. Is there disparity between risk and incidence of cardiovascular disease after liver transplant? Transplantation 2004; 77: 93-99.
20. Laryea M, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007; 13: 1109-1114.
21. Laish I, Braun M, Mor E, Sulkes J, Harif Y, Ben Ari Z,. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl 2011; 17: 15-22.
22. Viechtbauer W,. Conducting meta-analyses in R with the metafor package. J Stat Softw 2010; 36: 1-48.
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
24. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
25. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation 1998; 97: 1876-1887.
26. Lauer MS,. Clinical practice. Aspirin for primary prevention of coronary events. N Engl J Med 2002; 346: 1468-1474.
27. Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E,. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22) trial. J Am Coll Cardiol 2009; 54: 2358-2362.
28. Bostom AD, Brown RS Jr, Chavers BM, Coffman TM, Cosio FG, Culver K, et al. Prevention of post-transplant cardiovascular disease-report and recommendations of an ad hoc group. Am J Transplant 2002; 2: 491-500.
29. Foley RN, Parfrey PS, Sarnak MJ,. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (suppl 3): S112-S119.
30. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ,. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158-165.
31. Balla A, Chobanian M,. New-onset diabetes after transplantation: a review of recent literature. Curr Opin Organ Transplant 2009; 14: 375-379.
32. Israni AK, Snyder JJ, Skeans MA, Kasiske BL,; for PORT Investigators. Clinical diagnosis of metabolic syndrome: predicting new-onset diabetes, coronary heart disease, and allograft failure late after kidney transplant. Transpl Int 2012; 25: 748-757.
33. Faenza A, Fuga G, Nardo B, Donati G, Cianciolo G, Scolari MP, Stefoni S,. Metabolic syndrome after kidney transplantation. Transplant Proc 2007; 39: 1843-1846.
34. Kasiske BL, Chakkera HA, Roel J,. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735-1743.
35. Miller LW,. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002; 2: 807-818.
36. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS,. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977-983.
37. Rike AH, Mogilishetty G, Alloway RR, Succop P, Roy-Chaudhury P, Cardi M, et al. Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids. Clin Transplant 2008; 22: 229-235.
38. Segev DL, Sozio SM, Shin EJ, Nazarian SM, Nathan H, Thuluvath PJ, et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 2008; 14: 512-525.
39. Soveri I, Abedini S, Holdaas H, Jardine A, Eriksson N, Fellström B,. Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clin Transplant 2009; 23: 914-920.